양극성 장애 환자 수 분석과 예측(2026-2035년)

Global Bipolar Disorder Patient Population Analysis is projected to register a strong CAGR during the forecast period (2026-2035).

The growing recognition of bipolar disorder as a major contributor to the global mental health burden is encouraging healthcare systems to strengthen early diagnosis, patient monitoring, and long-term disease management, supporting the demand for comprehensive patient population analysis.

Bipolar disorder is a chronic psychiatric condition characterized by recurrent episodes of mania, hypomania, and depression that significantly affect emotional well-being, cognitive function, and daily life. It affects an estimated 37 million people globally, representing approximately 0.5% of the world's population, with the disease burden concentrated primarily among working-age adults. Although prevalence is similar in men and women, diagnostic rates tend to be higher among women in some healthcare settings. Delayed diagnosis, symptom overlap with other psychiatric disorders, and limited access to specialist care continue to contribute to underdiagnosis in many regions.

Patient population analysis provides valuable insights into disease prevalence, diagnosed and undiagnosed populations, incidence trends, age and gender distribution, disease severity, treatment eligibility, geographic variation, and future patient forecasts. These insights support pharmaceutical companies, healthcare providers, researchers, and policymakers in planning clinical development, healthcare resource allocation, and commercial strategies.

Market Drivers

Increasing Disease Recognition

Growing awareness of bipolar disorder among healthcare professionals and the general public is improving diagnosis rates worldwide. Expanded mental health education, improved screening protocols, and greater recognition of mood disorders in primary care settings are contributing to a larger diagnosed patient population.

Rising Mental Health Prioritization

Governments and healthcare organizations are increasing investment in mental health services as psychiatric disorders become a greater public health priority. Improved access to psychiatric care and community-based mental health programs is expected to strengthen patient identification and long-term disease management.

Expansion of Early Diagnosis Programs

Early diagnosis remains essential because many patients initially present with depressive symptoms before experiencing manic episodes. The adoption of structured screening tools, specialist referral pathways, and integrated mental healthcare services is improving diagnostic accuracy and supporting earlier intervention.

Growing Demand for Epidemiological Data

Pharmaceutical companies increasingly rely on detailed patient population analyses to estimate addressable patient populations, support clinical trial planning, evaluate market opportunities, and optimize commercialization strategies for emerging bipolar disorder therapies.

Market Restraints

Underdiagnosis and Misdiagnosis

The diverse clinical presentation of bipolar disorder frequently results in delayed diagnosis or misclassification as major depressive disorder or other psychiatric illnesses, affecting the accuracy of epidemiological estimates.

Persistent Social Stigma

Mental health stigma continues to discourage many individuals from seeking professional care, leading to delayed diagnosis and underreporting of disease prevalence in several regions.

Limited Access to Mental Healthcare

Many low- and middle-income countries continue to face shortages of psychiatrists, inadequate mental health infrastructure, and unequal access to specialized diagnostic services, limiting patient identification and long-term follow-up.

Epidemiology and Patient Population Insights

The global bipolar disorder patient population can be segmented by disease type, diagnosis status, age group, gender, disease severity, and geography.

By disease type, the patient population includes Bipolar I Disorder, Bipolar II Disorder, Cyclothymic Disorder, and other bipolar spectrum disorders. Bipolar I Disorder represents a substantial proportion of diagnosed patients due to its more pronounced manic episodes and greater likelihood of clinical recognition.

By diagnosis status, the market includes diagnosed patients, treated patients, and undiagnosed patient populations. Despite improvements in mental healthcare, a considerable number of individuals remain undiagnosed because of delayed presentation and symptom overlap with other psychiatric disorders.

By age group, the patient population includes pediatric, adolescent, adult, and geriatric patients. The highest prevalence is generally observed among young and middle-aged adults, highlighting the importance of early intervention and long-term disease management.

By disease severity, patients are classified according to mild, moderate, and severe functional impairment. Individuals with severe disease often require continuous psychiatric care, long-term pharmacological treatment, and psychosocial support.

Advances in electronic health records, artificial intelligence, predictive analytics, digital mental health platforms, and real-world evidence are improving epidemiological analysis, patient tracking, and healthcare planning.

Patient Population Trends

The bipolar disorder patient population is expected to expand steadily due to improved diagnosis and increasing awareness of mental health disorders.

Major epidemiological trends include:

• Increasing diagnosis through expanded mental health screening programs.
• Earlier detection among adolescents and young adults.
• Improved identification of previously undiagnosed patients.
• Greater use of digital mental health platforms for patient monitoring.
• Growing adoption of real-world evidence and healthcare databases for epidemiological research.
• Increased focus on long-term patient management and relapse prevention.

Regional Insights

North America accounts for a significant share of the diagnosed bipolar disorder population due to advanced mental healthcare infrastructure, widespread access to psychiatric specialists, comprehensive insurance coverage, and high disease awareness.

Europe remains an important market supported by established healthcare systems, improved mental health services, and increasing government investment in psychiatric care.

Asia-Pacific is expected to witness the fastest growth in diagnosed patient populations during the forecast period owing to expanding mental health awareness, improving healthcare infrastructure, increasing psychiatric services, and growing government initiatives across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually improving bipolar disorder diagnosis through expanded mental health programs, increasing public awareness, and strengthening healthcare infrastructure.

Competitive Landscape

The bipolar disorder patient population analysis landscape includes pharmaceutical companies, contract research organizations, epidemiology research firms, healthcare analytics providers, academic institutions, and government health agencies.

Organizations are increasingly utilizing real-world evidence, artificial intelligence, electronic medical records, national healthcare databases, and predictive epidemiological models to improve patient forecasting, clinical trial planning, healthcare resource allocation, and commercial strategy development.

Strategic collaborations between industry, academia, and healthcare organizations continue to strengthen epidemiological research and improve understanding of the global bipolar disorder patient population.

Future Outlook

The future of bipolar disorder patient population analysis is expected to be driven by advances in digital health, artificial intelligence, precision psychiatry, genomics, and integrated healthcare databases. Improved epidemiological modeling and patient identification will support earlier diagnosis, optimized treatment planning, and more efficient healthcare resource allocation.

Growing adoption of digital screening tools, telepsychiatry, and real-world evidence platforms is expected to improve patient identification while supporting pharmaceutical development and market access strategies.

Conclusion

The global Bipolar Disorder Patient Population Analysis market is expected to experience sustained growth through 2035, supported by increasing disease awareness, expanding mental healthcare services, improving diagnostic capabilities, and rising investment in epidemiological research. Although challenges related to underdiagnosis, social stigma, and healthcare accessibility remain, continued advances in digital health technologies, healthcare analytics, and precision psychiatry are expected to strengthen patient identification and provide valuable insights for healthcare providers, researchers, policymakers, and pharmaceutical companies.

Key Benefits of this Report

• Comprehensive analysis of the global bipolar disorder patient population and epidemiological trends.
• Detailed evaluation of prevalence, incidence, diagnosed and undiagnosed patient populations, and disease burden.
• Regional analysis supporting healthcare planning and commercial strategy.
• Insights into demographic trends, future patient forecasts, and unmet clinical needs.
• Valuable resource for pharmaceutical companies, biotechnology firms, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Patient population forecasting, epidemiology assessment, clinical trial planning, market opportunity evaluation, healthcare resource planning, commercial strategy development, investment analysis, and identification of future growth opportunities.

Report Coverage

• Historical data from 2021 to 2025, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global bipolar disorder patient population by disease type, diagnosis status, age group, gender, disease severity, and geography
• Evaluation of prevalence, incidence, diagnosed and undiagnosed populations, disease burden, and epidemiological trends
• Analysis of demographic distribution, healthcare utilization, patient forecasting, and treatment-eligible populations
• Assessment of regional epidemiology, mental healthcare infrastructure, diagnostic trends, and future patient growth opportunities
• Strategic outlook covering epidemiological developments, real-world evidence, digital health integration, and future patient population trends through 2035

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Global Bipolar Disorder Patient Population Overview
• 1.2 Key Epidemiology Highlights
• 1.3 Current Treatment Landscape Overview
• 1.4 Unmet Clinical and Therapeutic Needs
• 1.5 Pipeline Development Snapshot
• 1.6 Emerging Innovation Themes
• 1.7 Key Strategic Takeaways

2. Global Bipolar Disorder Patient Population Overview

• 2.1 Disease Definition and Clinical Classification
  • 2.1.1 Bipolar I Disorder
  • 2.1.2 Bipolar II Disorder
  • 2.1.3 Cyclothymic Disorder
  • 2.1.4 Other Specified and Unspecified Bipolar Disorders
• 2.2 Disease Burden Assessment
  • 2.2.1 Global Disease Burden
  • 2.2.2 Disability Burden
  • 2.2.3 Mortality and Suicide Risk
  • 2.2.4 Economic Burden
• 2.3 Epidemiology Framework
  • 2.3.1 Incident Cases
  • 2.3.2 Prevalent Cases
  • 2.3.3 Diagnosed Patient Population
  • 2.3.4 Treated Patient Population
  • 2.3.5 Eligible Patient Population for Emerging Therapies
• 2.4 Patient Segmentation Analysis
  • 2.4.1 Age-Based Distribution
  • 2.4.2 Gender-Based Distribution
  • 2.4.3 Disease Severity Distribution
  • 2.4.4 Disease Duration Distribution
  • 2.4.5 Comorbidity-Based Segmentation
• 2.5 Historical and Forecast Patient Trends
  • 2.5.1 Historical Patient Population Analysis
  • 2.5.2 Forecast Patient Population Analysis
  • 2.5.3 Growth Drivers
  • 2.5.4 Diagnostic Expansion Impact

3. Disease Biology and Unmet Need Analysis

• 3.1 Disease Pathophysiology
  • 3.1.1 Neurotransmitter Dysregulation
  • 3.1.2 Circadian Rhythm Dysfunction
  • 3.1.3 Neuroinflammation
  • 3.1.4 Neuroplasticity Impairment
• 3.2 Current Standard of Care Assessment
  • 3.2.1 Mood Stabilizers
  • 3.2.2 Antipsychotics
  • 3.2.3 Antidepressants
  • 3.2.4 Combination Therapies
• 3.3 Treatment Gaps and Limitations
  • 3.3.1 Delayed Diagnosis
  • 3.3.2 Inadequate Symptom Control
  • 3.3.3 High Relapse Rates
  • 3.3.4 Treatment Resistance
  • 3.3.5 Adverse Event Burden
• 3.4 Future Therapeutic Opportunities
  • 3.4.1 Precision Psychiatry
  • 3.4.2 Biomarker-Guided Treatment
  • 3.4.3 Digital Monitoring Integration
  • 3.4.4 Long-Acting Treatment Approaches

4. Mechanism of Action and Modality Landscape

• 4.1 Mechanism of Action Landscape Overview
• 4.2 Established Mechanistic Categories
  • 4.2.1 Dopamine Receptor Modulation
  • 4.2.2 Serotonin Receptor Modulation
  • 4.2.3 Glutamatergic Pathway Modulation
  • 4.2.4 GABAergic Modulation
  • 4.2.5 Multi-Receptor Modulation
• 4.3 Emerging Mechanistic Categories
  • 4.3.1 Neuroplasticity Enhancement
  • 4.3.2 Neuroinflammatory Pathway Modulation
  • 4.3.3 Circadian Rhythm Regulation
  • 4.3.4 Synaptic Function Restoration
  • 4.3.5 Novel CNS Signaling Targets
• 4.4 First-in-Class versus Best-in-Class Analysis
  • 4.4.1 First-in-Class Asset Assessment
  • 4.4.2 Best-in-Class Development Strategies
  • 4.4.3 Competitive Differentiation Framework
• 4.5 Modality Landscape
  • 4.5.1 Small Molecules
  • 4.5.2 Biologics
  • 4.5.3 Cell Therapies
  • 4.5.4 Gene Therapies
  • 4.5.5 RNA-Based Therapeutics
• 4.6 Innovation Index Assessment
  • 4.6.1 Novel Target Density
  • 4.6.2 Innovation Concentration by Phase
  • 4.6.3 Innovation Risk Assessment

5. Clinical Development Intelligence

• 5.1 Clinical Development Landscape
• 5.2 Trial Design Benchmarking
  • 5.2.1 Study Design Trends
  • 5.2.2 Randomization Approaches
  • 5.2.3 Control Arm Selection
  • 5.2.4 Adaptive Trial Utilization
• 5.3 Endpoint Assessment
  • 5.3.1 Primary Endpoint Trends
  • 5.3.2 Secondary Endpoint Trends
  • 5.3.3 Patient-Reported Outcomes
  • 5.3.4 Functional Outcome Measures
• 5.4 Clinical Development Metrics
  • 5.4.1 Sample Size Benchmarking
  • 5.4.2 Study Duration Analysis
  • 5.4.3 Recruitment Timelines
  • 5.4.4 Site Distribution Analysis
• 5.5 Clinical Success and Failure Intelligence
  • 5.5.1 Historical Success Rates
  • 5.5.2 Failure Drivers
  • 5.5.3 Trial Termination Trends
  • 5.5.4 Recruitment Challenges
  • 5.5.5 Patient Retention Analysis
• 5.6 Regulatory Development Trends
  • 5.6.1 Regulatory Guidance Review
  • 5.6.2 Expedited Program Utilization
  • 5.6.3 Approval Benchmarking

6. Bipolar Disorder Pipeline Segmentation Analysis

• 6.1 Pipeline Overview
  • 6.1.1 Total Active Assets
  • 6.1.2 Historical Pipeline Growth
  • 6.1.3 Sponsor Distribution
• 6.2 Pipeline by Development Phase
  • 6.2.1 Preclinical Assets
    • 6.2.1.1 Asset Inventory
    • 6.2.1.2 Mechanism Distribution
    • 6.2.1.3 Sponsor Analysis
  • 6.2.2 Phase I Assets
    • 6.2.2.1 Asset Inventory
    • 6.2.2.2 Mechanism Distribution
    • 6.2.2.3 Sponsor Analysis
  • 6.2.3 Phase II Assets
    • 6.2.3.1 Asset Inventory
    • 6.2.3.2 Mechanism Distribution
    • 6.2.3.3 Sponsor Analysis
  • 6.2.4 Phase III Assets
    • 6.2.4.1 Asset Inventory
    • 6.2.4.2 Mechanism Distribution
    • 6.2.4.3 Sponsor Analysis
  • 6.2.5 Filed / Under Review Assets
    • 6.2.5.1 Regulatory Status Assessment
    • 6.2.5.2 Approval Readiness Evaluation
• 6.3 Pipeline by Mechanism of Action
  • 6.3.1 Dopaminergic Therapies
  • 6.3.2 Serotonergic Therapies
  • 6.3.3 Glutamatergic Therapies
  • 6.3.4 Circadian Rhythm Therapies
  • 6.3.5 Neuroplasticity-Based Therapies
  • 6.3.6 Other Emerging Mechanisms
• 6.4 Pipeline by Modality
  • 6.4.1 Small Molecules
  • 6.4.2 Biologics
  • 6.4.3 Cell Therapies
  • 6.4.4 Gene Therapies
  • 6.4.5 RNA Therapies
• 6.5 Asset-Level Intelligence Profiles
  • 6.5.1 Molecule Overview
  • 6.5.2 Developer Assessment
  • 6.5.3 Mechanism of Action
  • 6.5.4 Clinical Development Status
  • 6.5.5 Key Trial Data
  • 6.5.6 Competitive Positioning
  • 6.5.7 Regulatory Outlook
  • 6.5.8 Commercial Potential
• 6.6 Historical Phase Progression Analysis
  • 6.6.1 Phase Transition Trends
  • 6.6.2 Time-to-Next-Phase Assessment
  • 6.6.3 Attrition Mapping

7. Probability of Success and Risk Analysis

• 7.1 Probability of Success Framework
• 7.2 Phase Transition Probability Modeling
  • 7.2.1 Preclinical to Phase I
  • 7.2.2 Phase I to Phase II
  • 7.2.3 Phase II to Phase III
  • 7.2.4 Phase III to Approval
• 7.3 Risk-Adjusted Pipeline Valuation
  • 7.3.1 Asset-Level Risk Adjustment
  • 7.3.2 Mechanism-Level Risk Adjustment
  • 7.3.3 Sponsor-Level Risk Adjustment
• 7.4 Attrition Analysis
  • 7.4.1 Historical Attrition Rates
  • 7.4.2 Mechanism-Specific Attrition
  • 7.4.3 Modality-Specific Attrition
• 7.5 Clinical and Commercial Risk Assessment
  • 7.5.1 Efficacy Risk
  • 7.5.2 Safety Risk
  • 7.5.3 Regulatory Risk
  • 7.5.4 Market Access Risk
• 7.6 Probability-Weighted Commercial Opportunity
  • 7.6.1 Risk-Adjusted Revenue Potential
  • 7.6.2 Portfolio Value Assessment
  • 7.6.3 Future Value Creation Potential

8. Launch Timeline and Commercial Potential

• 8.1 Expected Approval Timeline Analysis
• 8.2 Launch Sequencing Assessment
  • 8.2.1 Near-Term Launch Candidates
  • 8.2.2 Mid-Term Launch Candidates
  • 8.2.3 Long-Term Launch Candidates
• 8.3 Peak Sales Forecasting
  • 8.3.1 Asset-Level Peak Sales Potential
  • 8.3.2 Mechanism-Based Revenue Analysis
  • 8.3.3 Sponsor Revenue Opportunity
• 8.4 Market Penetration Modeling
  • 8.4.1 Eligible Population Assessment
  • 8.4.2 Adoption Curve Modeling
  • 8.4.3 Competitive Uptake Scenarios
• 8.5 Market Access and Reimbursement Outlook
  • 8.5.1 Pricing Dynamics
  • 8.5.2 Payer Considerations
  • 8.5.3 Health Economics Impact

9. Competitive Pipeline Landscape

• 9.1 Competitive Environment Overview
• 9.2 Company-Wise Pipeline Strength Assessment
  • 9.2.1 Leading Developers
  • 9.2.2 Emerging Challengers
  • 9.2.3 Academic and Nonprofit Contributors
• 9.3 Competitive Positioning Matrix
  • 9.3.1 Innovation Leadership
  • 9.3.2 Clinical Advancement Leadership
  • 9.3.3 Commercial Readiness Leadership
• 9.4 Asset Concentration Analysis
  • 9.4.1 Pipeline Concentration by Company
  • 9.4.2 Pipeline Concentration by Mechanism
  • 9.4.3 Pipeline Concentration by Modality
• 9.5 Competitive Benchmarking
  • 9.5.1 Clinical Differentiation
  • 9.5.2 Safety Differentiation
  • 9.5.3 Regulatory Differentiation
  • 9.5.4 Commercial Differentiation

10. Geographic Analysis (Regional Level Only)

• 10.1 North America
  • 10.1.1 Patient Population Analysis
  • 10.1.2 Clinical Trial Activity
  • 10.1.3 Regulatory Environment
  • 10.1.4 Innovation Hubs
• 10.2 Europe
  • 10.2.1 Patient Population Analysis
  • 10.2.2 Clinical Trial Activity
  • 10.2.3 Regulatory Environment
  • 10.2.4 Innovation Hubs
• 10.3 Asia-Pacific
  • 10.3.1 Patient Population Analysis
  • 10.3.2 Clinical Trial Activity
  • 10.3.3 Regulatory Environment
  • 10.3.4 Innovation Hubs
• 10.4 Latin America
  • 10.4.1 Patient Population Analysis
  • 10.4.2 Clinical Trial Activity
  • 10.4.3 Regulatory Environment
  • 10.4.4 Innovation Hubs
• 10.5 Middle East & Africa
  • 10.5.1 Patient Population Analysis
  • 10.5.2 Clinical Trial Activity
  • 10.5.3 Regulatory Environment
  • 10.5.4 Innovation Hubs

11. Key Countries Analysis

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 China
• 11.9 Japan
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Mexico
• 11.15 Saudi Arabia
• 11.16 South Africa

Standard Country-Level Framework (Applicable to Sections 11.1-11.16)

Trial Activity Assessment

Active Sponsors Analysis

Patient Population Trends

Regulatory Timeline Assessment

Market Access Environment

Emerging Development Opportunities

12. Deals and Investment Landscape

• 12.1 Strategic Partnership Landscape
• 12.2 Licensing Activity Analysis
  • 12.2.1 Early-Stage Licensing Deals
  • 12.2.2 Late-Stage Licensing Deals
• 12.3 Co-Development and Collaboration Analysis
  • 12.3.1 Research Collaborations
  • 12.3.2 Clinical Development Partnerships
• 12.4 Mergers and Acquisitions
  • 12.4.1 Asset Acquisition Trends
  • 12.4.2 Company Acquisition Trends
• 12.5 Financing Landscape
  • 12.5.1 Venture Capital Funding
  • 12.5.2 Private Equity Activity
  • 12.5.3 Public Market Financing
• 12.6 Investment Attractiveness Assessment
  • 12.6.1 High-Potential Mechanisms
  • 12.6.2 High-Potential Sponsors
  • 12.6.3 Emerging Investment Themes

13. Future Outlook and Strategic Insights

• 13.1 Pipeline Evolution Outlook
• 13.2 Emerging Innovation Trends
• 13.3 Future Standard-of-Care Scenarios
• 13.4 Competitive Market Evolution
• 13.5 Regulatory Outlook
• 13.6 Strategic Opportunities for Developers
• 13.7 Strategic Opportunities for Investors
• 13.8 Long-Term Market Forecast Scenarios

14. Methodology and Data Framework

• 14.1 Research Methodology
• 14.2 Data Sources and Validation Framework
  • 14.2.1 ClinicalTrials.gov
  • 14.2.2 EU Clinical Trials Information System (CTIS)
  • 14.2.3 Company Pipeline Disclosures
  • 14.2.4 Regulatory Filings
  • 14.2.5 Scientific Literature
• 14.3 Pipeline Inclusion Criteria
• 14.4 Asset Verification Methodology
• 14.5 Epidemiology Modeling Framework
• 14.6 Probability of Success Methodology
• 14.7 Commercial Forecasting Methodology
• 14.8 Risk Adjustment Methodology
• 14.9 Assumptions and Limitations
• 14.10 Glossary of Terms and Abbreviations